CSIMarket Company Name, Ticker, Suppliers, else..
 
Sage Therapeutics Inc   (NASDAQ: SAGE)
 
Price: $8.6800 $-0.02 -0.230%
Day's High: $8.74 Week Perf: -0.91 %
Day's Low: $ 8.68 30 Day Perf: -4.82 %
Volume (M): 22,698,600 52 Wk High: $ 0.00
Volume (M$): $ 197,024 52 Wk Avg: $0.00
Open: $8.74 52 Wk Low: $0.00



 Market Capitalization (Millions $) 543
 Shares Outstanding (Millions) 63
 Employees 353
 Revenues (TTM) (Millions $) 70
 Net Income (TTM) (Millions $) -301
 Cash Flow (TTM) (Millions $) -34
 Capital Exp. (TTM) (Millions $) 0

Business Description


Sage Therapeutics Inc is a biopharmaceutical company that develops and commercializes novel medicines for the treatment of central nervous system disorders. The company focuses on developing drugs that target the GABA pathway, which is involved in regulating the activity of neurons in the brain. Sage Therapeutics is known for its research in developing treatments for conditions such as postpartum depression, major depressive disorder, and movement disorders. The company is headquartered in Cambridge, Massachusetts, and is committed to improving the lives of individuals suffering from these debilitating disorders.


   Company Address: 55 Cambridge Parkway Cambridge 2142 MA
   Company Phone Number: 299-8380   Stock Exchange / Ticker: NASDAQ SAGE


   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
ABBV        0.38% 
BHC        3.8% 
LLY   -2.15%    
TEVA   -0.22%    
VRTX        0.82% 
VTRS        3.3% 
• View Complete Report
   



Business Update

In a significant development within the biopharmaceutical sector, Sage Therapeutics, Inc. confirmed it has ...

Published Sat, Jan 11 2025 9:37 AM UTC

Sage Therapeutics: Striking Acquisition Interest Amidst Unprecedented Revenue Surge In a significant development within the biopharmaceutical sector, Sage Therapeutics, Inc. confirmed it has received an unsolicited, nonbinding proposal from Biogen Inc. to acquire the company for $7.22 per share. This proposal, aimed at acquiring all outstanding shares of Sage not already own...
Business Update

Navigating the Challenges of Alzheimers and Essential Tremor The Journey of Sage Therapeutics Amid Mixed Clinical Ou...

Published Tue, Oct 8 2024 11:47 AM UTC

Sage Therapeutics, Inc. has recently reported findings from two pivotal clinical studies evaluating newer treatments for neurological conditions, particularly Alzheimer s disease and essential tremor. This article interprets the topline results from the LIGHTWAVE study for dalzanemdor (SAGE-718) regarding mild cognitive impairment and mild dementia in Alzheimer s patients...
Business Update

Discontinuation of SAGE-324 Development Following Negative Phase 2 Results Implications for Essential Tremor Treatment

Published Thu, Sep 26 2024 11:47 AM UTC

Sage Therapeutics, Inc. has announced the cessation of its collaboration with Biogen regarding the SAGE-324 program, a move that follows the recent unfavorable outcomes of the Phase 2 KINETIC 2 Study. This decision marks a significant turn in the investigational treatment landscape for essential tremor (ET), as SAGE-324 was one of the promising candidates being explored for ...
Announcement

Rosen Law Firm Calls on Sage Therapeutics Investors Last Chance to Join Class Action Before October 28 Dead...

Published Tue, Sep 17 2024 4:05 PM UTC

Rosen Law Firm Urges Sage Therapeutics, Inc. Investors to Act Before Securities Class Action Deadline In a significant reminder for investors, Rosen Law Firm, a prominent and trusted global investor rights law firm, has announced the urging of Sage Therapeutics, Inc. (NASDAQ: SAGE) shareholders to secure counsel concerning an impending important deadline linked to a securiti...
Business Update

Navigating New Frontiers in Brain Health Sage Therapeutics Promising Journey with ZURZUVAE

Published Thu, Aug 1 2024 6:28 AM UTC

Sage Therapeutics: Advancing Brain Health Through Innovative Therapies and Strong Market Performance Sage Therapeutics, Inc. is at the forefront of transforming brain health through pioneering biopharmaceuticals targeting serious mood disorders, particularly postpartum depression (PPD). This article examines their recent achievements, focusing on the promising commercial...



Fundamental Analysis

Valuation Current
Price to Earnings PE Ratio (TTM) -
Price to Earnings PE Ratio (Expected) -
Price to Sales (TTM) 7.72
Price to Sales (Expected) -
Price to Book 1.47
PEG (TTM) -

Financial Strength Current
Quick Ratio 8.19
Working Capital Ratio 9.16
Leverage Ratio (MRQ) 0.15
Total Debt to Equity -
Interest Coverage (TTM) -
Debt Coverage (TTM) -

Per Share Current
Earnings (TTM) -4.91 $
Revenues (TTM) 1.12 $
Cash Flow (TTM) -
Cash 5.84 $
Book Value 5.89 $
Dividend (TTM) 0 $

Efficiency Current
Revenue per Employee (TTM) 199,462
Net Income per Employee (TTM) -853,244
Receivable Turnover Ratio (TTM) 5.52
Inventory Turnover Ratio (TTM) -
Asset Turnover Ratio (TTM) 0.14

Profitability Ratios Current
Gross Margin (MRQ) -
Operating Margin (MRQ) -170.46 %
Net Margin (MRQ) -156.83 %
Net Cash Flow Margin (MRQ) 70.32 %
Effective Tax Rate (TTM) -

Management Effectiveness Current
Return On Assets (TTM) -
Return On Investment (TTM) -
Return On Equity (TTM) -
Dividend Yield -
Pay out Ratio (TTM) -



Sage Therapeutics Inc's Segments
Corporate and Reconciling Items    100 % of total Revenue





Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.